Aphios Pharma

Cannabis-Based Therapeutics For Anxiety, Pain, Opioid Use Disorder & MS

Security Type: CAFES
Categories: Technology, Social Impact, Healthcare & Medical, Community & Lifestyle, Sports & Fitness
Min Investment: $250
Location: Woburn, MA
Offering Date: October 01, 2021
Expected Close Date: April 30, 2023
Target Raise: $50.00K-$1.00M
No. Investors: 79
Security Price: $1
Deal Notes: Green biotech developing sustained release nanoencapsulated cannabinoids for highly unmet chronic medical needs ESG opportunity addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis Aphios has spent $44 million to date on developing enabling drug manufacturing and drug delivery technologies Including $7.9M in peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH Established supercritical fluid manufacturing facility for 1,000 kg pharma-grade cannabinoids per yr under cGMP Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued patents and 4 provisionals We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change
Website: aphios.com

Number of Employees: 6
Cash: $1,284
Revenue: $0
Short Term Debt: $1,620
Cost of Goods: $0
Long Term Debt: $28,260
Net Income: $-29,635

Company Description

Aphios is developing enabling technology platforms designed to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Using these enabling technology platforms, Aphios and its collaborators are developing enhanced therapeutics for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders

Perks

250 - Aphios Pharma stress ball

500 - Aphios Pharma cotton hat

1000 - Aphios Pharma first aid duffel

10000 - Aphios Pharma beach chair

Key Deal Facts

Green biotech developing sustained release nanoencapsulated cannabinoids for highly unmet chronic medical needs
ESG opportunity addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis
Aphios has spent $44 million to date on developing enabling drug manufacturing and drug delivery technologies
Including $7.9M in peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH
Established supercritical fluid manufacturing facility for 1,000 kg pharma-grade cannabinoids per yr under cGMP
Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids
Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued patents and 4 provisionals
We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change

Deal Notes

Green biotech developing sustained release nanoencapsulated cannabinoids for highly unmet chronic medical needs ESG opportunity addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis Aphios has spent $44 million to date on developing enabling drug manufacturing and drug delivery technologies Including $7.9M in peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH Established supercritical fluid manufacturing facility for 1,000 kg pharma-grade cannabinoids per yr under cGMP Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued patents and 4 provisionals We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change

Amount Raised : $93,791

Reveal the Score by Voting

＿

Additional ratings from other users are needed to determine a viable CrowdScore for this deal.

The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.

ⓘ

The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.

Business Idea

ⓘ

The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.

Business Traction

ⓘ

The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.

Management Team

ⓘ

The value of the company compared to similar companies raising money from investors.

Valuation

Have you done enough research to provide a rating? This is important for your fellow investors.

We only allow one revision to each rating category. Be sure about any changes.

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter

Read Our Research Disclaimer

0 Comments

To claim your deal, you must have access to @aphios.com email

Contact support@crowdlustro.com if you need assistance.

@aphios.com